Background: Hepatocellular carcinoma (HCC) is frequently resistant to chemotherapy.
However, epidermal growth factor receptor (EGFR) inhibition has demonstrated activity in …

4604 Background: Hepatocellular carcinomas (HCC) are known to express EGFR, and a ph
II study of erlotinib suggested clinical activity of EGFR inhibition. Combinations with EGFR …

BACKGROUND. The authors conducted a phase 2 trial of the antiepidermal growth factor
receptor (EGFR) monoclonal antibody cetuximab in combination with the gemcitabine plus …

The only approved systemic therapy for patients with advanced hepatocellular carcinoma
(HCC) till now is sorafenib. A preliminary study suggested that capecitabine, an oral …

4117 Background: This is a single arm, multi-center, phase II study to assess the efficacy
and tolerability of sorafenib, oxaliplatin and capecitabine combination for the treatment of …

Background: This is a single arm, multi-centre, phase II study to assess the efficacy and
tolerability of sorafenib combining oxaliplatin and capecitabine for the treatment of advanced …

Abstract Lessons Learned There continues to be a lack of systemic options for advanced
hepatocellular carcinoma (HCC); sorafenib and, very recently, regorafenib are the only …

4594 Background: A promising efficacy of the GEMOX combination was previously reported
in HCC. Moreover, the EGFR signalling pathway is involved in hepatic carcinogenesis and …

Background No standard second-line treatments are available for hepatocellular carcinoma
patients who fail sorafenib therapy. We assessed the safety and efficacy of metronomic …

4574 Background: Hepatocellular carcinoma (HCC) is one of the most common cancers
globally and its incidence of in USA is increasing. Unfortunately, most patients with HCC are …